{
    "eid": "2-s2.0-85125553283",
    "title": "Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results",
    "cover-date": "2022-03-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Radiology, Nuclear Medicine and Imaging",
            "@code": "2741",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "177Lu-FAP-2286",
        "adenocarcinoma",
        "fibroblast activation protein",
        "first-in-humans",
        "peptidetargeted radionuclide therapy"
    ],
    "authors": [
        "Richard P. Baum",
        "Christiane Schuchardt",
        "Aviral Singh",
        "Maythinee Chantadisai",
        "Franz C. Robiller",
        "Jingjing Zhang",
        "Dirk Mueller",
        "Alexander Eismant",
        "Frankis Almaguel",
        "Dirk Zboralski",
        "Frank Osterkamp",
        "Aileen Hoehne",
        "Ulrich Reineke",
        "Christiane Smerling",
        "Harshad R. Kulkarni"
    ],
    "citedby-count": 79,
    "ref-count": 31,
    "ref-list": [
        "The role of stromal cancer-associated fibroblasts in pancreatic cancer",
        "Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction",
        "Cancer-associated fibroblasts: their characteristics and their roles in tumor growth",
        "Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers",
        "Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics",
        "Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells",
        "Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes",
        "Molecular imaging of fibroblast activity after myocardial infarction using a 68Ga-labeled fibroblast activation protein inhibitor, FAPI-04",
        "Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer",
        "A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer",
        "RG7386, a novel tetravalent FAP-DR5 antibody, effectively triggers FAP-dependent, avidity-driven DR5 hyperclustering and tumor cell apoptosis",
        "OMTX705, a novel FAPtargeting ADC demonstrates activity in chemotherapy and pembrolizumabresistant solid tumor models",
        "Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold",
        "Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein",
        "Preclinical evaluation of FAP-2286. a peptide-targeted radionuclide therapy (PTRT) to fibroblast activation protein alpha (FAP) [abstract]",
        "Radiolabeling of DOTA-like conjugated peptides with generator-produced 68Ga and using NaCl-based cationic elution method",
        "A new automated NaCl based robust method for routine production of gallium-68 labeled peptides",
        "Radiolabeling and stability of FAP-seeking radiopharmaceuticals for radio-molecular imaging and therapy [abstract]",
        "The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using 177Lu-DOTATATE, 177Lu-DOTANOC, and 177Lu-DOTATOC",
        "68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer",
        "Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors",
        "[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study",
        "PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka experience since 2013",
        "Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC",
        "Post-therapeutic dosimetry of 177Lu-DKFZPSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer",
        "Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes",
        "May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET?. A pilot report on 188Re-HEDP treatment in progressive bone metastases after 177Lu-octreotate",
        "DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy",
        "Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu- and 225Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models"
    ],
    "affiliation": [
        {
            "affiliation-city": "Loma Linda",
            "@id": "60113483",
            "affilname": "Loma Linda University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60113483",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60026680",
            "affilname": "NUS Yong Loo Lin School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026680",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Berga",
            "@id": "60018973",
            "affilname": "Zentralklinik Bad Berka",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60018973",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Wiesbaden",
            "@id": "125045767",
            "affilname": "Center for Advanced Radiomolecular Precision Oncology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/125045767",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Berlin",
            "@id": "109577531",
            "affilname": "3B Pharmaceuticals GmbH",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/109577531",
            "affiliation-country": "Germany"
        }
    ],
    "funding": []
}